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Abstract
Background: Acute coronary syndrome (ACS) is common in patients approaching the end-of-life (EoL), but these patients
rarely receive palliative care. We compared the utility of a palliative care prognostic tool (Gold Standards Framework (GSF))
and the Global Registry of Acute Coronary Events (GRACE) score, to help identify patients approaching EoL.
Methods and Findings: 172 unselected consecutive patients with confirmed ACS admitted over an eight-week period were
assessed using prognostic tools and followed up for 12 months. GSF criteria identified 40 (23%) patients suitable for EoL
care while GRACE identified 32 (19%) patients with $10% risk of death within 6 months. Patients meeting GSF criteria were
older (p=0.006), had more comorbidities (1.660.7 vs. 1.260.9, p=0.007), more frequent hospitalisations before (p=0.001)
and after (0.0001) their index admission, and were more likely to die during follow-up (GSF+ 20% vs GSF- 7%, p=0.03).
GRACE score was predictive of 12-month mortality (C-statistic 0.75) and this was improved by the addition of previous
hospital admissions and previous history of stroke (C-statistic 0.88).
Conclusions: This study has highlighted a potentially large number of ACS patients eligible for EoL care. GSF or GRACE
could be used in the hospital setting to help identify these patients. GSF identifies ACS patients with more comorbidity and
at increased risk of hospital readmission.
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Introduction
The importance of well-coordinated supportive care at end of
life (EoL) is increasingly recognised as more people survive into old
age with multiple chronic long term conditions. While significant
improvements have been made in palliative care for cancer
patients, this is not so for patients with heart disease. In the last 10
years there have been many calls for better EoL care for people
with advanced heart failure [1–5] with little or no attention to
other chronic heart conditions where very similar issues apply such
as advanced valvular heart disease, congenital heart disease and
coronary heart disease syndromes. Despite calls for better EoL
care there continues to be a lack of research examining ways in
which it could be integrated into normal clinical care pathways
especially in the acute hospital setting. We know that cardiac
patients generally receive limited information about their condi-
tion and have poor access to EoL care services [6,7]. Furthermore,
EoL care is often poorly co-ordinated, with inadequate commu-
nication and cohesion between primary care, cardiologists and
palliative care specialists [8,9]. These problems have been
attributed to clinicians being in a state of ‘‘prognostic paralysis’’,
uncertain about the illness trajectory of heart disease and thus
uncertain about when to initiate EoL care planning [10].
Acute coronary syndrome is a common precursor to, and cause
of, death, particularly in the elderly. Indeed, the use of high
sensitivity troponin assays has resulted in many patients being
redirected from more generalist medical care to acute cardiology
services where they often receive excellent cardiac care but rarely
benefit from additional multi-dimensional support which they
might need [11]. A recent study found that nearly 25% of all ACS
patients over the age of 75 years were significantly frail with
increased short term mortality [12].
Focusing clinicians on the task of identifying patients with a
prognosis of less than a year is increasingly recognised as useful
trigger to raise awareness of the need for EoL care, as well as
cardiac care, in the acute hospital setting. There is a clear need to
explore, develop and test the utility of prognostic tools that could
assist clinicians to recognise such patients particularly in the acute
hospital setting.
The Gold Standards Framework (GSF) was initially developed
for cancer patients and more recently was broadened to include
chronic neurological, lung, kidney and heart disease [13]. It aims
to identify people approaching the end-of-life using clinical and
functional criteria that were derived and agreed using expert
clinical opinion and consensus (see Table 1). Many of these criteria
are subjective and have never been validated in a prospective
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contrast, is based on clinical data from over 100,000 patients
presenting to hospital with ACS and has been extensively
validated in numerous prospective studies [15–18].
This study aimed to assess two specific issues. Firstly, to
compare the utility of the GSF (GSF) criteria and the GRACE
score in identifying patients discharged from hospital following an
admission with acute coronary syndrome that may be approaching
the last year of life. Secondly, to assess the prevalence and clinical
characteristics of ACS patients who meet criteria for EoL care.
Methods
Subjects
Consecutive unselected ACS patients from one health authority
region admitted to a large urban-based hospital cardiology unit
over a two month period were included. All patients had a
confirmed diagnosis of acute coronary syndrome according to
national guidelines [19] including at least 2 of the following :
typical cardiac chest pain, a rise in plasma markers of cardiac
injury and electrocardiographic evidence of myocardial ischaemia
or infarction. Since we aimed to focus on EoL needs following
discharge, patients admitted with ACS who died in hospital were
excluded from analysis.
Data collection and interviews with medical staff
Data were collected from patient records prior to discharge on
specifically designed audit forms by research staff. These forms
included data fields for the various GSF criteria, clinical and
biochemical parameters required to calculate the GRACE score.
Members of the medical team caring for the patient during their
in-patient stay had brief training on the content of the GSF and
were interviewed to obtain data for the GSF criteria including the
Karnofsky performance score [20], assessment of recent general
physical decline, presence of ongoing difficult symptoms. These
medical staff also provided an answer to the ‘‘surprise question’’
(see Table 1). According to the GSF criteria, patients who score
positively on one general criterion and two heart-disease specific
criteria would benefit from a review for EoL care needs.
Clinical follow-up
Follow-up at 6 and 12 months was undertaken using a hospital-
based electronic patient record system and all-cause mortality
events were checked using a national central health index
database.
Ethical considerations
All data were collected and collated anonymously and stored
according to the Data Protection Act, United Kingdom (1998).
The study was granted audit status by South East Scotland
Research Ethics service as part of a clinical implementation project
assessing the use of the GSF in a hospital setting. No patients were
interviewed and there was no specific patient intervention.
Statistical analysis and data handling
The GRACE score was calculated for each patient using a web-
based calculator available from the GRACE website as a raw score
(range 40–220). The raw score was used to define low,
intermediate and high risk tertiles and is also presented as a
percentage 6 month mortality risk based on the discharge to 6
month follow up algorithm (see http://www.outcomes-umassmed.
org/grace/).
Data are expressed as mean6 standard deviation unless
otherwise stated. Analysis was carried out using Student’s t-test
for continuous data and Chi square and Fisher’s Exact tests for
categorical data. Variables with significant trend (P,0.1) were
entered in Cox proportional-hazards regression survival model to
identify factors independently affecting mortality. Statistical
significance was accepted at the 5% level. For parameters
demonstrating significance in the multivariate analysis, survival
curves were computed using the Kaplan–Meier method. ROC
curves were plotted using predicted vs. actual mortality with
GRACE risk alone and combination of GRACE with stroke and
admissions. PASW Statistics 18 software (IBM corporation, New
York, USA) was used for analysis.
Results
Patient characteristics
172 patients were included in the study (Table 2). In summary,
60% were male with mean age 66 years. At presentation, the mean
heart rate was 76/minute, mean systolic blood pressure
140 mmHg and mean creatinine 103 umol/l. Troponin was
elevated in 70%, ST segment deviation on the electrocardiogram
was present in 56% and 26% had evidence of heart failure during
admission. Two or more additional comorbidities were present in
37% (61) including for example diabetes, arthritis, chronic lung
disease, stroke, or chronic kidney disease. The majority of patients
were treated appropriately according to national guidelines with
evidence based drugs with no significant differences in use of
invasive strategy in those that survived compared with those that
died within 12 months (Table 2).
Identifying End of Life using GSF
Defining a positive GSF status as one general criterion plus two
heart disease criteria identified 40 (23%) patients as approaching
EoL. During follow-up, GSF positive patients were more likely to
die than GSF negative patients (20% vs 7%, p=0.03). GSF
positive patients had a significantly greater number of additional
comorbidities (1.660.7 vs 1.260.9, p=0.007) and were more
likely to have recurrent hospital admissions both before and after
their index admission for this study (Table 2).
Using only two heart disease criteria to define EoL would have
been identified 47 patients (27%) as GSF positive. Using the GSF
‘surprise’ question as the sole prognostic indicator would have
identified 38 (22%) patients likely to die within the next 6 to 12
months. General physical decline was identified in 45 patients
Table 1. Gold Standards Framework criteria.
General Criteria of End-stage illness (at least one of these)
N Weight loss .10% in last 6 months
N General physical decline
N Serum albumin ,25 g/l
N Reducing performance status (Karnofsky score ,50%)
Heart Disease specific criteria (at least 2 of these)
N The ‘‘Surprise Question’’ (to be asked of a health care provider familiar
with the patient): ‘‘Would you be surprised if this patient died in the next 6 to
12 months?’’
N New York Heart Association (NYHA)– Stage III or IV heart failure
N Repeated hospital admissions within the last year
N Difficult physical or psychological symptoms despite optimised tolerated
therapy
doi:10.1371/journal.pone.0035536.t001
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performance score in 24 (14%). Weight loss, as defined in the GSF,
was a difficult to assess mainly because most patients were unaware
of their previous and current weight and so this could not be
accurately assessed across the whole cohort. There were no patients
with albumin levels lower than 25 g/l in whole cohort.
Identifying End of Life using GRACE
The GRACE risk score was not significantly higher in patients
who were GSF positive using one general and two heart disease
criteria (Table 3). In this consecutive cohort of unselected patients,
GRACE identified 72(42%) patients with a $5%, 32 (19%)
patients with a $10% and 8 (5%) patients with a $20% risk of
death within 6 months from discharge. Patients with a 6 month
mortality risk of $10% had significantly more co-morbidities
(1.5+0.8 vs 1.2+0.9, P=0.014) and a higher proportion were GSF
positive (50% vs 17%, p=.0.003) compared with patients with a
GRACE risk of less than 10%. Combining GSF positive patients
with an estimated GRACE risk of death of 10% or more would
have identified 16 (10%) patients as suitable for EoL care.
Table 2. Baseline patient characteristics and alive versus dead by 12 months comparison.
All patients (n=172) Alive (n=155) Dead (n=17) ttest/Chi/Fisher
Age 66614 64614 7968 ,0.00001
Gender (Males,%) 61 62 53 0.64
GRACE score criteria (mean6SD)
Heart rate (min
21)7 6 . 2 619.3 76.2619.0 76.4622.5 0.96
Systolic blood pressure (mmHg) 140.8627.0 140.7627.2 142.2625.0 0.83
Creatinine (mmol/l) 103.1652.1 101.7653.2 116.3640.4 0.29
Killip Class (1–4) 1.360.5 1.360.5 1.460.6 0.27
Cardiac arrest (%) 4 4 0
ST deviation (%) 56 56 53 0.50
Elevated troponin (%) 65 63 77 0.21
Probability in-hospital death (%) 3.465.3 2.663.0 9.0611.7 ,0.0001
Probability in-hospital death/MI (%) 12.366.5 11.966.3 15.567.6 0.08
Probability 6 month death (%) 6.066.7 5.566.4 10.967.5 ,0.001
Probability 6 month death/MI (%) 17.669.1 12.166.6 23613.2 ,0.001
GSF criteria (mean6SD)
Albumin (g/dl) 41.064.1 41.164.0 40.264.6 0.34
Surprise question ‘‘No’’ (%) 22 21 35 0.14
GSF-End stage illness (n) 0.760.8 0.660.8 1.160.9 0.05
GSF-Heart Disease (n) 1.061.2 1.061.1 1.661.3 0.03
GSF-Combined criteria (n,%) 23 21 20 0.02
12 months prior to admission (n) 0.360.6 0.360.6 0.660.9 0.02
12 months following admission (n) 1.261.7 1.061.4 2.862.8 ,0.0001
Co-morbidity
Total co-morbidities (n, mean6SD)) 1.360.9 1.360.9 1.660.8 0.08
Previous Stroke (%) 8.7 7.7 17.6 0.17
Diabetes (%) 23 23 18 0.43
COPD (%) 6 5 24 0.01
CKD (%) 8 6 24 0.04
Other comorbidity (%) 68 67 76 0.32
In-patient/discharge treatment (%)
Aspirin 94.2 94.8 88.2 0.25
Clopidogrel 93.6 93.5 94.1 0.33
Heparin 98.8 99.4 94.1 0.20
Statin 79.7 80.6 70.6 0.51
ACE inhibitor 65.1 65.2 64.7 0.57
Beta blocker 58.7 59.4 52.9 0.61
Angiography 69.8 70.3 64.7 0.59
Percutaneous intervention 48.8 47.7 58.8 0.45
P values for alive versus dead comparison, GSF – Gold Standards Framework, SD standard deviation, ST – electrocardiogram ST segment, COPD – chronic obstructive
pulmonary disease, CKD – chronic kidney disease.
doi:10.1371/journal.pone.0035536.t002
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At 6 months, 6 patients had died while a further 11 died by 12
months. Patients that died by 12 months follow-up (n=17) had a
significantly higher discharge raw GRACE score (146620 vs
115632, p=0.0001) and consequently had a significantly higher
estimated mortality risk (10.967.5% vs 5.566.4%, p=0.001).
Based on tertiles, GRACE score at discharge was highly predictive
of death (Table 4) clearly distinguishing between those at low,
medium and high risk of death by 12 months (Figure 1). Patients
that died were significantly more likely to have had non-elective
hospital admission during the year prior to their index admission
(p=0.02) and were also more likely to have readmission during 12
month follow-up (p=,0.0001, Table 2). GSF positive patients
had a significantly greater number of readmissions during follow-
up compared with GSF negative patients (2.462.6 vs 0.861.2,
p,0.0001). After correction for other factors, the GRACE risk
score (tertiles), previous stroke and 3 or more previous non-elective
hospital admissions within the last year were independently
predictive of death (Table 4 and Figure 1).
Sensitivity and specificity of GRACE and GSF for 12
month all-cause mortality
The sensitivity and specificity of GRACE and GSF in predicting
12 month mortality are summarised in Table 5. Both approaches
provided a reasonable specificity although this was higher for the
GRACE score. Using a cut-off of 20% for GRACE did not
improve the sensitivity or specificity in predicting death. The
predictive value of GRACE, however, improved with addition of
stroke comorbidity and hospital admissions (Figure 2) with an
increase in the area under the ROC curve from 0.75 to 0.88.
Discussion
This unique study has highlighted a potentially large number of
patients presenting to hospital with ACS who could benefit from
enhanced supportive care as they approach end of life. GSF and
GRACE, used independently, would identify around 20% of an
unselected cohort of ACS patients presenting to a large urban
hospital as suitable for EoL care according to agreed criteria
developed for cancer patients.
In the United Kingdom, these patients could be included on
palliative care registers held by community physicians who then
ensure that patients receive an assessment of their care-needs,
develop an advanced care plan which includes detailed discussion
with the patient of future aspects of management and resuscitation
status. This type of care planning, sometimes referred to as
advanced care planning, is associated with reduced readmission to
hospital [21–23]. However, to date, there are little or no data
available to assess the resources that would be required to deliver
this to a high standard for all eligible patients. Our study is the first
that we are aware of to highlight this in a disease specific way.
The number of patients referred for EoL care could be more
than halved if the GRACE and GSF tools were used in
combination. However, this combined approach would miss a
significant number of patients nearing EoL who might benefit
from this care. The negative predictive power would be strong
however and so if a patient was GSF negative and had an
estimated mortality risk of less than 5% at discharge then they
would be very unlikely to die or be readmitted within the following
12 months. Furthermore, patients identified as requiring EoL care
by either GRACE or GSF in our study were older, had more
comorbidity, were more likely to be readmitted during follow up
and had higher mortality than those who did not meet these
criteria. This would suggest that in addition to identifying risk-of-
Table 3. Clinical characteristics and outcomes of Gold
standards Framework (GSF) positive (defined as meeting 1
general criterion and 2 heart disease criteria) versus Gold
Standards Framework negative patients.
GSF
positive
GSF
negative
P (ttest/
Fisher)
(n=40) (n=132)
Age (years) 71612 64614 0.006
Male (%) 62.5 60.6 0.76
Death by 12 months (%(n)) 20.0 (8) 6.8 (9) 0.03
Additional comorbidities (n) 1.760.7 1.260.9 0.004
GRACE criteria
Heart rate (min
21) 81.4621.7 74.7618.3 0.10
Systolic BP (mmHg) 140629 141627 0.7
Creatinine (mmol/l) 107632 102657 0.6
ECG ST deviation (%) 47.5 4.5 0.001
Elevated troponin (%) 70.0 58.3 0.25
Killip class (1–4) 1.560.6 1.260.5 0.0005
GRACE 6 month death risk (%) 6.167.0 6.066.6 0.92
Admissions (n)
12 months prior to admission 0.860.8 0.260.5 0.001
12 months following admission 2.462.6 0.861.2 0.0001
doi:10.1371/journal.pone.0035536.t003
Figure 1. Kaplan-Meier survival curves for factors independently predicting all-cause mortality.
doi:10.1371/journal.pone.0035536.g001
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patients with greater needs and who are at risk of hospital
readmission. Our findings are similar to a recent study assessing
frailty in elderly ACS patients [12]. This is not unexpected since
the GSF criteria used in our study contain measures of functional
status similar to those used in frailty assessment scores. However,
we have gone further by raising the issue that these patients could
benefit from an advanced care plan combined with extra-
supportive care in the community and indeed some may benefit
from review by a palliative care specialist.
Acute coronary syndrome in elderly patients, as defined by
cardiac symptoms with elevation of plasma biomarkers, has
become increasingly common with the introduction of high
sensitivity troponin assays [24]. Cardiac injury may occur with
other chronic conditions associated with ageing such as chronic
kidney disease [25], chronic lung disease [26] and pulmonary
embolic disease [27], all of which are common conditions in
elderly people admitted to hospital. In these clinical settings
clinicians should perhaps be acknowledging ACS as a syndrome
associated with the end of life. This concept does not in any way
imply that such patients should not receive optimal evidence-based
therapies during their in-patient stay, this should be assured.
However, the clear challenge is to use an admission with ACS in
an elderly patient with multiple co-morbidities as an opportunity
to carefully consider the global functional status of the patient.
Thereafter, expert clinical judgement combined with appropriate
clinical data should be used to increasingly provide extra
supportive care while continuing to provide disease modifying
treatment, a concept now realised in cancer-care. The findings of
this study have clearly highlighted the need for such a change in
approach.
Our study indicated that many ACS patients with the increased
care needs could be identified by asking the ‘surprise’ question
although further assessment using GSF criteria or GRACE score
would be necessary. Patients highlighted by medical staff as at risk
of dying within 6 to 12 months were older, had more co-morbidity
and scored lower on functional status. In fact, our findings suggest
that asking hospital doctors to assess patients during a relatively
short in-patient stay using the ‘surprise’ question would have
strong negative predictive accuracy in detecting ACS patients who
might be approaching EoL. Therefore, it seems appropriate that,
as a screening tool, doctors should be encouraged to ask
themselves the ‘surprise’ question when considering the illness
trajectory of their patients.
Limitations
There are several limitations to this study. Firstly, we studied a
relatively small number of patients, although with a fairly detailed
interview with the patient’s caring physician, and so further
research is warranted to examine many of the complex issues
Table 4. Univariate and multivariate analysis of factors
predicting all-cause mortality.
Uni-variate
1 Multivariate
2
Gender 0.5 N/A
GRACE score Tertiles 0.001 0.04
GSF General Criteria
General Physical decline 0.3 N/A
Albumin (,25) N/A
3 N/A
Karnofsky score 0.87 N/A
GSF Heart Criteria
Difficult symptoms 0.4 N/A
Surprise question 0.06 0.5
Repeated hospital admissions 0.001 0.001
Co-morbidities
Total co-morbidities (n) 0.3 N/A
Stroke 0.1 0.04
Diabetes 0.6 N/A
COPD 0.002 0.1
CKD 0.01 N/A
4
1p value from Kaplan Meier log-rank test.
2p value from Cox-regression analysis.
3No patient with less than 25 g/dl albumin.
4CKD is not independent risk factor as creatinine level included in GRACE score.
doi:10.1371/journal.pone.0035536.t004
Figure 2. ROC curve for predicted mortality from GRACE risk alone and combination of GRACE risk with previous stroke and
previous hospital admissions.
doi:10.1371/journal.pone.0035536.g002
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hospital setting who could benefit from EoL care. The GRACE
model does not incorporate non-cardiac co-morbidities and in this
setting these may play a more important role in management of
the patient. By interviewing different doctors over the 8 week
period of the study this may also have introduced the potential for
inter-observer variability. However, we did provide the same brief
education intervention to all doctors who provided interviews in a
way that could be replicated elsewhere. The multivariate analysis
is also limited by the small sample size and the relatively small
number of mortality events.
In conclusion, this study has highlighted a potentially large
number of cardiac patients admitted to hospital with ACS who by
various criteria, as defined by GRACE and the GSF, may be
approaching end of life. We have also demonstrated that both
prognostic tools have excellent rule-out utility and furthermore
they appear to identify a group of patients with increased care-
needs.
While further research is needed, the time has come for
cardiologists and physicians caring for ACS patients to consider, at
discharge, the need for extra supportive care in the community for
those identified as approaching end of life while not denying them
optimal evidence based care.
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